Shkreli, former company ask judge to find no wrongdoing in Daraprim lawsuit
Reuters
Published Nov 29, 2021 02:09PM ET
Updated Nov 29, 2021 03:32PM ET
WASHINGTON (Reuters) -Martin Shkreli, in jail on an unrelated matter, his former company Vyera Pharmaceuticals and others asked a judge Monday to find that they broke no laws in their handling of the drug Daraprim, which saw its price increase by more than 4,000% in one day.
The Federal Trade Commission filed a lawsuit in January 2020, alleging that the company that Shkreli once ran protected its dominance of the drug by restricting distribution to ensure generic drug makers could not get the samples needed to bring out a cheaper version of the drug. The company, formerly Turing Pharmaceuticals, also prevented potential competitors from buying an ingredient, the FTC said.
Daraprim, which is used to treat toxoplasmosis, saw its price go from $17.50 per tablet to $750. Toxoplasmosis is a common parasitic infection that generally causes serious problems only if the infected person has a weakened immune system.
In a filing on Monday, the defendants said that the FTC had failed to prove that the company hurt competition, since another drug -- Bactrim -- was also an effective treatment for toxoplasmosis. They also argued that other companies had been able to buy the key ingredient, pyrimethamine, contradicting an FTC allegation.
The government also failed to show that the defendants made any ill-gotten gains, they said in the filing.
Trial in the case is set to begin on Dec. 14 in the U.S. District Court for the District of Southern New York.
Shkreli, who is due to be released from prison in October 2022, became notorious when he sharply raised the price of the anti-parasitic drug Daraprim while chief executive of Turing Pharmaceuticals.
Shkreli had been convicted in August 2017 of cheating investors in two hedge funds he founded, and trying to prop up the stock price of biotechnology company Retrophin (NASDAQ:TVTX) Inc, which he once ran.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.